BR0007974A - Usos de um agente farmacologicamente ativo, deum constructo de gene e de um antìgeno, métodospara produzir uma composição farmacêutica em póe para administrar uma droga a um indivìduo emnecessidade dela, composição farmacêutica, formade dosagem unitária, e, artigo de manufatura parasuprimento transdérmico ou transmucoso de umagente farmacologicamente ativo a um indivìduo - Google Patents

Usos de um agente farmacologicamente ativo, deum constructo de gene e de um antìgeno, métodospara produzir uma composição farmacêutica em póe para administrar uma droga a um indivìduo emnecessidade dela, composição farmacêutica, formade dosagem unitária, e, artigo de manufatura parasuprimento transdérmico ou transmucoso de umagente farmacologicamente ativo a um indivìduo

Info

Publication number
BR0007974A
BR0007974A BR0007974-0A BR0007974A BR0007974A BR 0007974 A BR0007974 A BR 0007974A BR 0007974 A BR0007974 A BR 0007974A BR 0007974 A BR0007974 A BR 0007974A
Authority
BR
Brazil
Prior art keywords
individual
pharmacologically active
pharmaceutical composition
methods
administering
Prior art date
Application number
BR0007974-0A
Other languages
English (en)
Inventor
Barbara Horsey O'connor
Terry Lee Burkoth
Steven Josephprestrelski
Yuh-Fun Maa
Andrew Muddle
Rodney Hafner
Original Assignee
Powderject Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Powderject Res Ltd filed Critical Powderject Res Ltd
Publication of BR0007974A publication Critical patent/BR0007974A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors

Abstract

"USOS DE UM AGENTE FARMACOLOGICAMENTE ATIVO, DEUM CONSTRUCTO DE GENE E DE UM ANTìGENO, MéTODOSPARA PRODUZIR UMA COMPOSIçãO FARMACêUTICA EM PóE PARA ADMINISTRAR UMA DROGA A UM INDIVìDUO EMNECESSIDADE DELA, COMPOSIçãO FARMACêUTICA, FORMADE DOSAGEM UNITáRIA, E, ARTIGO DE MANUFATURA PARASUPRIMENTO TRANSDéRMICO OU TRANSMUCOSO DE UMAGENTE FARMACOLOGICAMENTE ATIVO A UM INDIVìDUO".São providas novas composições formadas da combinação deuma substância ativa com uma metade de veículo de hidrogel. Ascomposições são adequadas para uso em técnicas de injeçãotransdérmica de alta velocidade de partículas. São tambémfornecidos métodos de prover as novas composições. Além disso,são providos métodos para administrar agente farmacologicamenteativo a um indivíduo. Estes métodos são úteis para suprir drogas,biofarmacêuticos, vacinas e agentes diagnósticos.
BR0007974-0A 1999-02-03 2000-02-03 Usos de um agente farmacologicamente ativo, deum constructo de gene e de um antìgeno, métodospara produzir uma composição farmacêutica em póe para administrar uma droga a um indivìduo emnecessidade dela, composição farmacêutica, formade dosagem unitária, e, artigo de manufatura parasuprimento transdérmico ou transmucoso de umagente farmacologicamente ativo a um indivìduo BR0007974A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11833499P 1999-02-03 1999-02-03
PCT/GB2000/000349 WO2000045792A1 (en) 1999-02-03 2000-02-03 Hydrogel particle formulations

Publications (1)

Publication Number Publication Date
BR0007974A true BR0007974A (pt) 2001-10-30

Family

ID=22377934

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0007974-0A BR0007974A (pt) 1999-02-03 2000-02-03 Usos de um agente farmacologicamente ativo, deum constructo de gene e de um antìgeno, métodospara produzir uma composição farmacêutica em póe para administrar uma droga a um indivìduo emnecessidade dela, composição farmacêutica, formade dosagem unitária, e, artigo de manufatura parasuprimento transdérmico ou transmucoso de umagente farmacologicamente ativo a um indivìduo

Country Status (16)

Country Link
US (1) US7022313B2 (pt)
EP (1) EP1146861B1 (pt)
JP (1) JP2002536317A (pt)
KR (1) KR100845769B1 (pt)
CN (1) CN1230152C (pt)
AT (1) ATE298562T1 (pt)
AU (1) AU780397B2 (pt)
BR (1) BR0007974A (pt)
CA (1) CA2361555A1 (pt)
DE (1) DE60021059T2 (pt)
ES (1) ES2243229T3 (pt)
IL (2) IL144597A0 (pt)
MX (1) MXPA01007844A (pt)
NZ (1) NZ513538A (pt)
PT (1) PT1146861E (pt)
WO (1) WO2000045792A1 (pt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002538195A (ja) * 1999-03-08 2002-11-12 パウダージェクト リサーチ リミテッド 生物活性化合物の持続放出用の無針注射器を使用する微粒子製剤の送達
US20050214227A1 (en) * 1999-03-08 2005-09-29 Powderject Research Limited Microparticle formulations for sustained-release of bioactive compounds
KR101476574B1 (ko) 1999-10-29 2014-12-24 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
AU2001290678A1 (en) * 2000-09-08 2002-03-22 Powderject Research Limited Alginate particle formulation
MXPA03003895A (es) 2000-10-30 2003-07-28 Euro Celtique Sa Formulaciones de hidrocodona de liberacion controlada.
GB0103620D0 (en) * 2001-02-14 2001-03-28 Prometic Biosciences Ltd Sterile composition and its preparation
US7943067B2 (en) * 2001-08-16 2011-05-17 Polytechnic Institute Of New York University Nanogels and their production using liposomes as reactors
GB2404865B (en) * 2001-09-11 2005-09-28 Caretek Medical Ltd Novel drug delivery technology
AU2002366267B2 (en) * 2001-11-19 2007-05-10 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
JP2005522473A (ja) * 2002-04-10 2005-07-28 オブシェストヴォ ス オグラニシェノイ オトヴェトストベノスチユ《ヴィタゲル》 多官能価の生体適合性ヒドロゲル及びその生産方法
EP1356826A1 (en) * 2002-04-22 2003-10-29 BIOMAY Produktions- und Handels- Aktiengesellschaft Microparticles comprising carbohydrate beads covalently linked with allergen
GB0300008D0 (en) * 2003-01-02 2003-02-05 Optinose As Delivery devices
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1697035B1 (en) * 2003-12-22 2017-11-15 Warren H. Finlay Powder formation by atmospheric spray-freeze drying
ITRM20040168A1 (it) * 2004-04-01 2004-07-01 Sigma Tau Ind Farmaceuti Composizione a rilascio modificato ph dipendente.
KR100624450B1 (ko) 2004-12-10 2006-09-18 삼성전자주식회사 히드로겔을 이용한 생물분자의 분리 및 정제 방법
KR100624452B1 (ko) * 2004-12-21 2006-09-18 삼성전자주식회사 고정화된 히드로겔 또는 ｐｅｇ－히드로겔 공중합체를이용한 핵산의 분리 및 정제 방법
NZ543314A (en) * 2005-10-28 2007-08-31 Interag A delivery system where the driving substance contains the active component
US20070112592A1 (en) * 2005-11-17 2007-05-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Payments in providing assistance related to health
US10042980B2 (en) * 2005-11-17 2018-08-07 Gearbox Llc Providing assistance related to health
US20090238890A1 (en) * 2006-01-13 2009-09-24 Advanced Bionutrition Corporation Continuous spray-capture production system
EP2007358A4 (en) * 2006-04-04 2012-01-25 Stc Unm INFLATING PARTICLES FOR THE ADMINISTRATION OF A MEDICINAL PRODUCT
US8932634B2 (en) * 2006-06-15 2015-01-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Hydrocolloid carrier beads with inert filler material
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
JP2008096503A (ja) * 2006-10-06 2008-04-24 Toshiba Corp 粉末状感光性組成物の製造方法、感光性組成物およびこの感光性組成物から形成された光記録媒体
WO2009015037A2 (en) 2007-07-21 2009-01-29 Albany Molecular Research, Inc. 5-pyridinone substituted indazoles
US8093038B2 (en) * 2007-09-17 2012-01-10 Illinois Institute Of Technology Apparatus and method for encapsulating pancreatic cells
US9468607B2 (en) * 2007-10-09 2016-10-18 Washington University Ligand directed toroidal nanoparticles for therapy and diagnostic imaging
EP2209420A4 (en) 2007-10-09 2014-01-22 Univ St Louis IMAGING PARTICLES
US8293510B2 (en) * 2007-11-16 2012-10-23 University Of Kansas Method of preparing a hydrogel network encapsulating cells
EP2628727A3 (en) 2007-11-21 2013-12-25 Decode Genetics EHF Biaryl PDE4 inhibitors for treating pulmonary and cardiovascular disorders
AU2009204048B2 (en) 2008-01-11 2013-08-01 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as MCH antagonists
WO2009108760A2 (en) 2008-02-26 2009-09-03 Board Of Regents, The University Of Texas System Dendritic macroporous hydrogels prepared by crystal templating
EP2589392B1 (en) * 2008-03-05 2016-11-30 Sanofi Pasteur Process for stabilizing an adjuvant containing vaccine composition
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
RU2506266C2 (ru) 2009-01-26 2014-02-10 Израэл Инститьют Фо Байолоджикал Рисерч Бициклические гетероциклические спиросоединения
HUE028642T2 (en) * 2009-04-20 2016-12-28 Galen Bio Inc Preparations for incorporating biomolecules into cells
AU2010340067B2 (en) 2009-12-15 2015-03-19 Incept, Llc Implants and biodegradable fiducial markers
US9808500B2 (en) 2009-12-17 2017-11-07 Washington University Antithrombotic nanoparticle
US9764043B2 (en) 2009-12-17 2017-09-19 Washington University Antithrombotic nanoparticle
CA2787598A1 (en) * 2010-01-24 2012-06-21 Novartis Ag Irradiated biodegradable polymer microparticles
AU2011239414A1 (en) 2010-04-15 2012-11-08 The Washington University Prodrug compositions, prodrug nanoparticles, and methods of use thereof
US8927025B2 (en) 2010-05-11 2015-01-06 Cima Labs Inc. Alcohol-resistant metoprolol-containing extended-release oral dosage forms
US8946194B2 (en) 2010-10-08 2015-02-03 Board Of Regents, University Of Texas System One-step processing of hydrogels for mechanically robust and chemically desired features
EP2624874A4 (en) 2010-10-08 2014-04-02 Univ Texas ADHESIVE MEMBRANE WITH ALGINATE AND HYALURONIC ACID FOR BIOMEDICAL APPLICATIONS
US9849089B2 (en) * 2010-10-14 2017-12-26 Amorepacific Corporation Hydrogel particle coated with lipid and method for manufacturing same
US10092660B2 (en) * 2011-04-25 2018-10-09 Stc.Unm Solid compositions for pharmaceutical use
KR101255520B1 (ko) * 2011-10-28 2013-04-23 한국과학기술원 이중충하이드로젤 미세입자의 비등방성 부품을 이용한 미세수송체의 제조방법
US11565027B2 (en) 2012-12-11 2023-01-31 Board Of Regents, The University Of Texas System Hydrogel membrane for adhesion prevention
WO2015065547A1 (en) 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
KR102038751B1 (ko) * 2016-11-18 2019-10-30 연세대학교 산학협력단 복합 제형이 적용된 마이크로니들 어레이 및 이의 제조방법
KR102129986B1 (ko) * 2018-08-30 2020-07-03 포항공과대학교 산학협력단 일산화질소 감응성을 갖는 아크릴아마이드계 고분자를 포함하는 염증성 질환 예방 또는 치료용 약학 조성물
US10799564B1 (en) 2019-05-06 2020-10-13 Baxter International Inc. Insulin premix formulation and product, methods of preparing same, and methods of using same
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
KR102407470B1 (ko) * 2021-08-09 2022-06-10 인제대학교 산학협력단 하이드로겔에 담지된 약물의 방출량 검출 방법

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5036006A (en) * 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
JPH0725689B2 (ja) * 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
SE456486B (sv) * 1987-03-27 1988-10-10 Ralf Andersson Sett och anordning for uppdelning av en smelta i droppar
US4994276A (en) * 1988-09-19 1991-02-19 Edward Mendell Co., Inc. Directly compressible sustained release excipient
US4925677A (en) * 1988-08-31 1990-05-15 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
US5041292A (en) * 1988-08-31 1991-08-20 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
US5053332A (en) * 1989-07-24 1991-10-01 Cook Richard B Agarose beads, preferably incorporating biological materials
WO1991007487A1 (en) 1989-11-16 1991-05-30 Duke University Particle-mediated transformation of animal tissue cells
DK0454044T3 (da) * 1990-04-25 1996-04-22 Hoechst Ag Farmakologisk præparat indeholdende polyelektrolytkomplekser på mikropartikelform og mindst et virksomt stof
GB9014871D0 (en) * 1990-07-05 1990-08-22 Erba Carlo Spa Drug delivery system for administering growth factor
WO1994009819A1 (en) 1992-11-03 1994-05-11 Secretech, Inc. Microcrystalline cellulose as an immune adjuvant
TW360548B (en) * 1993-04-08 1999-06-11 Powderject Res Ltd Products for therapeutic use
EP0727984B1 (en) * 1993-11-18 2003-06-25 Sirtex Medical Limited Controlled release preparation
GB9416663D0 (en) 1994-08-17 1994-10-12 Oxford Bioscience Limited Particle delivery
DE69507321T2 (de) 1994-10-24 1999-07-15 Powderject Res Ltd Nadellose spritze
GB9426379D0 (en) 1994-12-23 1995-03-01 Oxford Biosciences Ltd Particle delivery
GB9502879D0 (en) 1995-02-14 1995-04-05 Oxford Biosciences Ltd Particle delivery
GB9605690D0 (en) 1996-03-19 1996-05-22 Oxford Biosciences Ltd Particle delivery
GB9612629D0 (en) * 1996-06-17 1996-08-21 Oxford Biosciences Ltd Method for providing dense particle compositions for use in transdermal particle delivery
GB9619002D0 (en) * 1996-09-11 1996-10-23 Oxford Biosciences Ltd Particle delivery
AU4940197A (en) 1996-09-26 1998-04-17 Wanzl Metallwarenfabrik Gmbh Device and method for the purchasing of goods
US6656508B2 (en) * 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
EP0888790A1 (en) 1997-07-04 1999-01-07 PowderJect Research Limited Drug particle delivery device
EP0888791A1 (en) 1997-07-04 1999-01-07 PowderJect Research Limited Syringe and drug capsule therefor
CA2342832A1 (en) 1998-09-04 2000-03-16 Powderject Research Limited Immunodiagnostics using particle delivery methods
CA2342801A1 (en) 1998-09-04 2000-03-16 Powderject Research Limited Monitoring methods using particle delivery methods
US5952232A (en) 1998-09-17 1999-09-14 Rothman; James Edward Expandible microparticle intracellular delivery system
EP1117382B1 (en) 1998-10-01 2005-05-11 PowderJect Research Limited Spray coated microparticles for use in needleless syringes
WO2000043058A1 (en) 1999-01-22 2000-07-27 Powderject Research Limited Method of enhancing needleless transdermal powdered drug delivery

Also Published As

Publication number Publication date
KR20010101994A (ko) 2001-11-15
KR100845769B1 (ko) 2008-07-11
DE60021059D1 (de) 2005-08-04
ATE298562T1 (de) 2005-07-15
AU2309200A (en) 2000-08-25
ES2243229T3 (es) 2005-12-01
US7022313B2 (en) 2006-04-04
US20020061336A1 (en) 2002-05-23
AU780397B2 (en) 2005-03-17
IL144597A (en) 2007-03-08
EP1146861A1 (en) 2001-10-24
MXPA01007844A (es) 2005-06-06
WO2000045792A8 (en) 2001-11-29
WO2000045792A1 (en) 2000-08-10
NZ513538A (en) 2004-02-27
IL144597A0 (en) 2002-05-23
JP2002536317A (ja) 2002-10-29
CN1345232A (zh) 2002-04-17
CA2361555A1 (en) 2000-08-10
DE60021059T2 (de) 2006-05-18
PT1146861E (pt) 2005-10-31
EP1146861B1 (en) 2005-06-29
CN1230152C (zh) 2005-12-07

Similar Documents

Publication Publication Date Title
BR0007974A (pt) Usos de um agente farmacologicamente ativo, deum constructo de gene e de um antìgeno, métodospara produzir uma composição farmacêutica em póe para administrar uma droga a um indivìduo emnecessidade dela, composição farmacêutica, formade dosagem unitária, e, artigo de manufatura parasuprimento transdérmico ou transmucoso de umagente farmacologicamente ativo a um indivìduo
NO20043871L (no) Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid
NO953278L (no) Fremgangsmåter for in vivo-levering av biologisk aktive stoffer og sammensetninger som er nyttige for dette
HK1050313A1 (en) Oral transmucosal drug dosage using solid solution
AR039744A1 (es) Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
ATE387430T1 (de) Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
SG166775A1 (en) Combinations and modes of administration of therapeutic agents and combination therapy
EE03805B1 (et) Peroraalselt manustatava farmatseutilise kompositsiooni kasutamine meeste erektiilse talitlushäire raviks ettenähtud ravimi valmistamiseks
HK1106126A1 (zh) 順序的藥劑輸送系統
ATE292453T1 (de) Antivirale arznei
NZ595127A (en) Stable pharmaceutical composition for atherosclerosis
HUP0300290A2 (hu) Érkárosító hatású kombinácíós készítmény és terápia
EP0888054A4 (en) TARGET-SPECIFIC MEDICINE ADMINISTRATION COMPOSITIONS AND METHODS OF USE
AP2003002763A0 (en) Controlled release formulations for oral administration
BR0211198A (pt) Composições farmacêuticas e seu uso
ATE311904T1 (de) Halbfester verabreichungsträger und arzneimittel
CO5200854A1 (es) Formulaciones farmaceuticas orales en capsulas de gelatina de hidroxipropilmetil celulosa que comprenden un derivado de camptotecina dentro de una matriz semisolida de polietilenglicol
BRPI0413374A (pt) composições para liberação de base fraca por um perìodo estendido de tempo
DE68929117T2 (de) Chemische Verbindungen und pharmazeutische Zusammensetzungen zur Freisetzung von Arzneimitteln
DE60007074D1 (de) Sulfatierte phosphatidylinositole, ihre herstellung und verwendung
WO2005030132A3 (en) Therapeutic regimens for administering drug combinations
DE69803772T2 (de) Oral anzuwendende feste arzneizubereitungen mit modulierter wirkstoffabgabe enthaltend nicorandil und verfahren zu deren herstellung
AR029415A1 (es) Pirroles sustituidos, un procedimiento para su preparacion, composicion farmaceutica, y el uso de dichos compuestos para la preparacion de medicamentos
WO2007016146A3 (en) Method for retarding systemic delivery rate for easily absorbable active agents
SG146671A1 (en) Therapeutic regimens for administering drug combinations

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM ARTIGOS 8O, 10( VIII ), 13 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.